Beyond BCG: The Approaching Era of Personalised Bladder-Sparing Therapies for Non-Muscle-Invasive Urothelial Cancers

References

• Ross JS , GreeneB. Targeted therapy in oncology: the agony and ecstasy of personalized medicine. Expert Rev. Anticancer Ther.1(3), 321–322 (2001).
   PubMedGoogle Scholar
• Herrmann JL , RastelliL, BurgessCEet al. Implications of oncogenomics for cancer research and clinical oncology. Cancer J.7(1), 40–51 (2001).
   PubMed Web of Science ®Google Scholar
• Zoon KC . Future directions in cancer research: impact of the completion of the human genome. Toxicol. Pathol.32(Suppl. 1), 1–2 (2004).
   PubMedGoogle Scholar
• Epstein RJ . Growth of the Asian health-care market: global implications for the pharmaceutical industry. Nat. Rev. Drug Discov.6(10), 785–792 (2007).
   PubMed Web of Science ®Google Scholar
• Basik M , MoussesS, TrentJ. Integration of genomic technologies for accelerated cancer drug development. BioTechniques35(3), 580–582; 584–586 passim (2003).
   PubMed Web of Science ®Google Scholar
• Epstein RJ . Unblocking blockbusters: using boolean text-mining to optimise clinical trial design and timeline for novel anticancer drugs. Cancer Inform.7, 231–238 (2009).
   PubMedGoogle Scholar
• Epstein RJ . Has discovery-based cancer research been a bust?Clin. Transl. Oncol.15(11), 865–870 (2013).
   PubMed Web of Science ®Google Scholar
• Berger T , SaundersME, MakTW. Beyond the oncogene revolution: four new ways to combat cancer. Cold Spring Harb. Symp. Quant. Biol.81, 85–92 (2016).
   PubMedGoogle Scholar
• Eagles JR , JimenoA. Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma. Drugs Today52(11), 593–605 (2016).
   PubMed Web of Science ®Google Scholar
• Baselga J , CortésJ, KimS-Bet al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med.366(2), 109–119 (2012).
   PubMed Web of Science ®Google Scholar
• Logan C , BrownM, HayneD. Intravesical therapies for bladder cancer - indications and limitations. BJU Int.110(Suppl. 4), 12–21 (2012).
   PubMedGoogle Scholar
• Babjuk M , BöhleA, BurgerMet al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol.71(3), 447–461 (2017).
   PubMed Web of Science ®Google Scholar
• Yang LS , ShanBL, ShanLLet al. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg. Oncol.25(3), 281–297 (2016).
   PubMed Web of Science ®Google Scholar
• Witjes JA , CompératE, CowanNCet al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol.65(4), 778–792 (2014).
   PubMed Web of Science ®Google Scholar
• Sahu D , LotanY, WittmannB, NeriB, HanselDE. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Med.6(9), 2106–2120 (2017).
   PubMed Web of Science ®Google Scholar
• Piyarathna DWB , RajendiranTM, PutluriVet al. Distinct lipidomic landscapes associated with clinical stages of urothelial cancer of the bladder. Eur. Urol. Focus doi:https://doi.org/10.1016/j.euf.2017.04.005 (2017).
   PubMedGoogle Scholar
• Ilijazi D , AbufarajM, HasslerMR, ErtlIE, D’AndreaD, ShariatSF. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. Expert Rev. Mol. Diagn.18(4), 347–356 (2018).
   PubMed Web of Science ®Google Scholar
• Castillo-Martin M , Domingo-DomenechJ, Karni-SchmidtO, MatosT, Cordon-CardoC. Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol.28(4), 401–408 (2010).
   PubMed Web of Science ®Google Scholar
• Khandelwal P , AbrahamSN, ApodacaG. Cell biology and physiology of the uroepithelium. Am. J. Physiol. Renal Physiol.297(6), F1477–F1501 (2009).
   PubMed Web of Science ®Google Scholar
• Kobayashi T , OwczarekTB, McKiernanJM, Abate-ShenC. Modelling bladder cancer in mice: opportunities and challenges. Nat. Rev. Cancer15(1), 42–54 (2014).
   Web of Science ®Google Scholar
• Chan KS , EspinosaI, ChaoMet al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA106(33), 14016–14021 (2009).
   PubMed Web of Science ®Google Scholar
• Ohishi T , KogaF, MigitaT. Bladder cancer stem-like cells: their origin and therapeutic perspectives. Int. J. Mol. Sci.17(1), pii: E43 (2015).
   PubMed Web of Science ®Google Scholar
• Colopy SA , BjorlingDE, MulliganWA, BushmanW. A population of progenitor cells in the basal and intermediate layers of the murine bladder urothelium contributes to urothelial development and regeneration. Dev. Dyn.243(8), 988–998 (2014).
   PubMed Web of Science ®Google Scholar
• Brandt WD , MatsuiW, RosenbergJEet al. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev.28(3–4), 291–304 (2009).
   PubMed Web of Science ®Google Scholar
• Czerniak B , DinneyC, McConkeyD. Origins of bladder cancer. Annu. Rev. Pathol.11(1), 149–174 (2016).
   PubMedGoogle Scholar
• Balsara ZR , LiX. Sleeping beauty: awakening urothelium from its slumber. Am. J. Physiol. Renal Physiol.312(4), F732–F743 (2017).
   PubMed Web of Science ®Google Scholar
• Vartolomei MD , Porav-HodadeD, FerroMet al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol. Oncol.36(9), 389–399 (2018).
   PubMed Web of Science ®Google Scholar
• Kang M , JeongCW, KwakC, KimHH, KuJH. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget8(8), 12891–12901 (2017).
   PubMedGoogle Scholar
• Paner GP , StadlerWM, HanselDE, MontironiR, LinDW, AminMB. Updates in the eighth edition of the Tumor-Node-Metastasis staging classification for urologic cancers. Eur. Urol.73(4), 560–569 (2018).
   PubMed Web of Science ®Google Scholar
• Eble JN , YoungRH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin. Diagn. Pathol.14(2), 98–108 (1997).
   PubMed Web of Science ®Google Scholar
• Sauter G , AlgabaF, AminMet al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs. EbleJN, SauterG, EpsteinJI, SesterhennIA ( Eds). IARCC Press, Lyon, France, 90–150 (2004).
   Google Scholar
• Epstein JI , AminMB, ReuterVR, MostofiFK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol.22(12), 1435–1448 (1998).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ , Van Der MeijdenAP, OosterlinckWet al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–465; discussion 475–467 (2006).
   PubMed Web of Science ®Google Scholar
• McKenney JK , GomezJA, DesaiS, LeeMW, AminMB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am. J. Surg. Pathol.25(3), 356–362 (2001).
   PubMed Web of Science ®Google Scholar
• Van Batavia J , YamanyT, MolotkovAet al. Bladder cancers arise from distinct urothelial sub-populations. Nat. Cell Biol.16(10), 982–991 (2014).
   PubMed Web of Science ®Google Scholar
• Shin K , LimA, OdegaardJIet al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol.16(5), 469–478 (2014).
   PubMed Web of Science ®Google Scholar
• Woldu SL , BagrodiaA, LotanY. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int.119(3), 371–380 (2017).
   PubMed Web of Science ®Google Scholar
• Chang SS , BoorjianSA, ChouRet al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol.196(4), 1021–1029 (2016).
   PubMed Web of Science ®Google Scholar
• Jäger W , ThomasC, HaagSet al. Early vs delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int.108(8 Pt 2), e284–e288 (2011).
   PubMedGoogle Scholar
• Khochikar M . Early vs delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int.108(8 Pt 2), e288–e289 (2011).
   PubMedGoogle Scholar
• Hartmann A , RösnerU, SchlakeGet al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab. Invest.80(5), 709–718 (2000).
   PubMed Web of Science ®Google Scholar
• Jones TD , WangM, EbleJNet al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin. Cancer Res.11(18), 6512–6519 (2005).
   PubMed Web of Science ®Google Scholar
• Stoehr R , HartmannA, HiendlmeyerE, MürleK, WielandW, KnuechelR. Oligoclonality of early lesions of the urothelium as determined by microdissection-supported genetic analysis. Pathobiology68(4-5), 165–172 (2000).
   PubMed Web of Science ®Google Scholar
• Acar Ö , ÖzkurtE, DemirGet al. Determining the origin of synchronous multifocal bladder cancer by exome sequencing. BMC Cancer15(1), 871 (2015).
   PubMedGoogle Scholar
• Nordentoft I , LamyP, Birkenkamp-DemtröderKet al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep.7(5), 1649–1663 (2014).
   PubMed Web of Science ®Google Scholar
• Lamy P , NordentoftI, Birkenkamp-DemtröderKet al. Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma. Cancer Res.76(19), 5894–5906 (2016).
   PubMed Web of Science ®Google Scholar
• Kawanishi H , TakahashiT, ItoMet al. Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation. Br. J. Cancer97(2), 260–266 (2007).
   PubMed Web of Science ®Google Scholar
• Kawanishi H , TakahashiT, ItoMet al. High throughput comparative genomic hybridization array analysis of multifocal urothelial cancers. Cancer Sci.97(8), 746–752 (2006).
   PubMed Web of Science ®Google Scholar
• Hartmann A , MoserK, KriegmairM, HofstetterA, HofstaedterF, KnuechelR. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am. J. Pathol.154(3), 721–727 (1999).
   PubMed Web of Science ®Google Scholar
• Obermann EC , MeyerS, HellgeDet al. Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. Oncol. Rep.11(4), 745–751 (2004).
   PubMed Web of Science ®Google Scholar
• Junker K , BoernerD, SchulzeW, UttingM, SchubertJ, WernerW. Analysis of genetic alterations in normal bladder urothelium. Urology62(6), 1134–1138 (2003).
   PubMed Web of Science ®Google Scholar
• Guo Y , ChekalukY, ZhangJet al. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J. Pathol.230(1), 17–27 (2013).
   PubMed Web of Science ®Google Scholar
• Rebouissou S , HéraultA, LetouzéEet al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J. Pathol.227(3), 315–324 (2012).
   PubMed Web of Science ®Google Scholar
• Simoneau M , LarueH, AboulkassimTO, MeyerF, MooreL, FradetY. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene19(54), 6317–6323 (2000).
   PubMed Web of Science ®Google Scholar
• Majewski T , LeeS, JeongJet al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab. Invest.88(7), 694–721 (2008).
   PubMed Web of Science ®Google Scholar
• Czerniak B , ChaturvediV, LiLet al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene18(5), 1185–1196 (1999).
   PubMed Web of Science ®Google Scholar
• Chaturvedi V , LiL, HodgesSet al. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene14(17), 2059–2070 (1997).
   PubMed Web of Science ®Google Scholar
• Chai H , BrownRE. Field effect in cancer – an update. Ann. Clin. Lab. Sci.39(4), 331–337 (2009).
   PubMed Web of Science ®Google Scholar
• Wolff EM , ChiharaY, PanFet al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res.70(20), 8169–8178 (2010).
   PubMed Web of Science ®Google Scholar
• Rentsch CA , MüllerDC, RuizC, BubendorfL. Comprehensive molecular characterization of urothelial bladder carcinoma: a step closer to clinical translation?Eur. Urol.72(6), 960–961 (2017).
   PubMed Web of Science ®Google Scholar
• Sánchez-Carbayo M . Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol.33(2), 347–361 (2012).
   PubMedGoogle Scholar
• Nordling CO . A new theory on cancer-inducing mechanism. Br. J. Cancer7(1), 68–72 (1953).
   PubMed Web of Science ®Google Scholar
• Hedegaard J , LamyP, NordentoftIet al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell30(1), 27–42 (2016).
   PubMed Web of Science ®Google Scholar
• Glaser AP , FantiniD, ShilatifardA, SchaefferEM, MeeksJJ. The evolving genomic landscape of urothelial carcinoma. Nat. Rev. Urol.14(4), 215–229 (2017).
   PubMed Web of Science ®Google Scholar
• Pietzak EJ , BagrodiaA, ChaEKet al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur. Urol.72(6), 952–959 (2017).
   PubMed Web of Science ®Google Scholar
• Lindgren D , FrigyesiA, GudjonssonSet al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res.70(9), 3463–3472 (2010).
   PubMed Web of Science ®Google Scholar
• Lindgren D , SjödahlG, LaussMet al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE7(6), e38863 (2012).
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C . Molecular alterations associated with bladder cancer initiation and progression. Scand. J. Urol. Nephrol. Suppl.42(218), 154–165 (2008).
   Google Scholar
• Kim M-S , JeongJ, MajewskiTet al. Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia. Lab. Invest.86(2), 175–190 (2006).
   PubMed Web of Science ®Google Scholar
• Lee S , JeongJ, MajewskiTet al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc. Natl Acad. Sci. USA104(34), 13732–13737 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan L , GuX, ShaoJet al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol.29(10), 611–617 (2010).
   PubMed Web of Science ®Google Scholar
• Di Martino E , TomlinsonDC, KnowlesMA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv. Urol.2012(6), 1–10 (2012).
   Google Scholar
• Iyer G , MilowskyMI. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol. Oncol.31(3), 303–311 (2013).
   PubMed Web of Science ®Google Scholar
• Breyer J , WirtzRM, OttoWet al. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget8(40), 67684–67695 (2017).
   PubMedGoogle Scholar
• Di Martino E , L’HôteCG, KennedyW, TomlinsonDC, KnowlesMA. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene28(48), 4306–4316 (2009).
   PubMed Web of Science ®Google Scholar
• Jebar AH , HurstCD, TomlinsonDC, JohnstonC, TaylorCF, KnowlesMA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene24(33), 5218–5225 (2005).
   PubMed Web of Science ®Google Scholar
• López-Knowles E , HernándezS, MalatsNet al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res.66(15), 7401–7404 (2006).
   PubMed Web of Science ®Google Scholar
• López-Knowles E , HernándezS, KogevinasMet al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin. Cancer Res.12(20 Pt 1), 6029–6036 (2006).
   PubMed Web of Science ®Google Scholar
• Zieger K , MarcussenN, BorreM, OrntoftTF, Dyrskj⊘tL. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int. J. Cancer125(9), 2095–2103 (2009).
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C , ZhangZF, DalbagniGet al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res.57(7), 1217–1221 (1997).
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW , LurkinI, RadvanyiF, KirkelsWJ, Van Der KwastTH, ZwarthoffEC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res.61(4), 1265–1268 (2001).
   PubMed Web of Science ®Google Scholar
• Burger M , Van Der AaMN, Van OersJMet al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol.54(4), 835–843 (2008).
   PubMed Web of Science ®Google Scholar
• Van Kessel KE , Van Der KeurKA, Dyrskj⊘tLet al. Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups. Clin. Cancer Res.24(7), 1586–1593 (2018).
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW , ZuiverloonTC, VisANet al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur. Urol.58(3), 433–441 (2010).
   PubMed Web of Science ®Google Scholar
• Duenas M , Martinez-FernandezM, Garcia-EscuderoRet al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol. Carcinog.54(7), 566–576 (2015).
   PubMed Web of Science ®Google Scholar
• Breyer J , WirtzRM, OttoWet al. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol. Immunother.144(11), 646 (2017).
   Google Scholar
• Sjödahl G , LaussM, LövgrenKet al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res.18(12), 3377–3386 (2012).
   PubMed Web of Science ®Google Scholar
• Network CGaR . Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507(7492), 315–322 (2014).
   PubMed Web of Science ®Google Scholar
• Damrauer JS , HoadleyKA, ChismDDet al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. USA111(8), 3110–3115 (2014).
   PubMed Web of Science ®Google Scholar
• Choi W , PortenS, KimSet al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell25(2), 152–165 (2014).
   PubMed Web of Science ®Google Scholar
• Lerner SP , McConkeyDJ, HoadleyKAet al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer2(1), 37–47 (2016).
   PubMedGoogle Scholar
• Perou CM , S⊘rlieT, EisenMBet al. Molecular portraits of human breast tumours. Nature406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Choi W , OchoaA, McConkeyDJet al. Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur. Urol.72(3), 354–365 (2017).
   PubMed Web of Science ®Google Scholar
• Sjödahl G , LövgrenK, LaussMet al. Toward a molecular pathologic classification of urothelial carcinoma. Am. J. Pathol.183(3), 681–691 (2013).
   PubMed Web of Science ®Google Scholar
• Dadhania V , ZhangM, ZhangLet al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine12, 105–117 (2016).
   PubMed Web of Science ®Google Scholar
• Rebouissou S , Bernard-PierrotI, De ReynièsAet al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med.6(244), 244ra291 (2014).
   Web of Science ®Google Scholar
• Sjödahl G , ErikssonP, LiedbergF, HöglundM. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol.242(1), 113–125 (2017).
   PubMed Web of Science ®Google Scholar
• Sharron Lin X , HuL, SandyKet al. Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: applying RNA-sequencing analysis on archived specimens. Urol Oncol32(3), 327–336 (2014).
   PubMed Web of Science ®Google Scholar
• Dyrskj⊘t L , ZiegerK, KruhofferMet al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer Res.11(11), 4029–4036 (2005).
   PubMed Web of Science ®Google Scholar
• Dyrskj⊘t L , ZiegerK, RealFXet al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res.13(12), 3545–3551 (2007).
   PubMed Web of Science ®Google Scholar
• Wang R , MorrisDS, TomlinsSAet al. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res.69(9), 3810–3818 (2009).
   PubMed Web of Science ®Google Scholar
• Mo Q , NikolosF, ChenFet al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J. Natl Cancer Inst.8(11), 631 (2018).
   Google Scholar
• Dyrskj⊘t L , ReinertT, AlgabaFet al. Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study. 72(3), 461–469 (2017).
   Google Scholar
• Dubosq F , PloussardG, SolimanHet al. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder. Urol. Oncol.30(6), 833–840 (2012).
   PubMed Web of Science ®Google Scholar
• Breyer J , WirtzRM, OttoWet al. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch.470(3), 267–274 (2017).
   PubMed Web of Science ®Google Scholar
• Guagnano V , FuretP, SpankaCet al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem.54(20), 7066–7083 (2011).
   PubMed Web of Science ®Google Scholar
• Di Stefano AL , FucciA, FrattiniVet al. Detection, characterization, and inhibition of FGFR–TACC fusions in IDH wild-type glioma. Clin. Cancer Res.21(14), 3307–3317 (2015).
   PubMed Web of Science ®Google Scholar
• Hahn NM , BivalacquaTJ, RossAEet al. A Phase II trial of dovitinib in bcg-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clin. Cancer Res.23(12), 3003–3011 (2017).
   PubMed Web of Science ®Google Scholar
• Chen C-H , ChangouC, HsiehT-Het al. Dual inhibition of PIK3C3 and FGFR as a new therapeutic approach to treat bladder cancer. Clin. Cancer Res. doi:https://doi.org/10.1158/1078-0432.CCR-17-2066 clincanres.2066.2017 (2017).
   Web of Science ®Google Scholar
• Davarpanah NN , YunoA, TrepelJB, ApoloAB. Immunotherapy: a new treatment paradigm in bladder cancer. Curr. Opin. Oncol.29(3), 184–195 (2017).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-CensitsJ, PowlesTet al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase 2 trial. Lancet387(10031), 1909–1920 (2016).
   PubMed Web of Science ®Google Scholar
• Sharma P , RetzM, Siefker-RadtkeAet al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, Phase 2 trial. Lancet Oncol.18(3), 312–322 (2017).
   PubMed Web of Science ®Google Scholar
• Siddiqui MR , GrantC, SanfordT, AgarwalPK. Current clinical trials in non-muscle invasive bladder cancer. Urol. Oncol.35(8), 516–527 (2017).
   PubMed Web of Science ®Google Scholar
• Hurst CD , AlderO, PlattFMet al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell32(5), 701–715.e707 (2017).
   PubMed Web of Science ®Google Scholar